Amyloid-β precursor protein synthesis inhibitors for Alzheimer's disease treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Discovery of MAO-B Inhibitor with Machine Learning, Topomer CoMFA, Molecular Docking and Multi-Spectroscopy Approaches.Biomolecules · 2022
   Article
2. Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5'-untranslated region: Implications in Alzheimer's disease.Molecular psychiatry · 2019
   Article
3. Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine.Journal of biomedical science · 2017
   Review
4. (-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice.Cell transplantation
   Article

Corrections and comments

• Commented on by
  Reply: To PMID 24687915.2014
• Comment on
  Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.2014

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as